Barclays says Humana (HUM) and Alignment Healthcare (ALHC) traded down yesterday amid Medicare Advantage star rating confusion. The selloffs were due to due to concerns around 2025 star ratings impacting 2026 plan revenue, driven by what could have been a potential technical glitch on the Medicare Plan Finder website, the analyst tells investors in a research note. When the Medicare Advantage Plan Finder website goes live, it displays the latest star rating for each plan. Because 2025 stars have not been released by the Centers for Medicare and Medicaid Services, the website shows “Star rating: Coming Soon” for this year’s plans, says Barclays. Filtering plans by stars indicates Humana’s largest contract H5216 and Alignment’s H3815 contract no longer hold four star ratings, whereas CVS Health’s (CVS) two large contracts H5521 and H5522 remain above four stars, the firm points out. Following Tuesday’s close, it remains unclear whether the Plan Finder website is a reliable indicator of stars, according to Barclays. The firm’s analysis of the 650 plan documents released for CVS signals the company is well positioned for margin improvement.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana (NYSE:HUM) Reveals 2025 Medicare Advantage Plans
- Humana Grapples with Sharp Decline in Medicare Star Ratings
- Humana falls after releasing 2025 Medicare Advantage offerings
- Health insurers unveil 2025 Medicare Advantage plans, Reuters reports
- Barclays sees margin benefits from Humana, CVS Medicare Advantage exits